Laryngeal cancer is one of the most common malignant cancer of the head and neck. Concurrent chemoradiotherapy is considered by the NCCN guideline to be the most effective organ protection strategy for locally advanced laryngeal cancer, which can preserve the larynx without reducing the survival rate of patients. Patients with non-T4 （T1-3） and high lymph node burden （N2-3） laryngeal cancer can benefit from concurrent chemoradiotherapy, which are more suitable for concurrent chemoradiotherapy than locally advanced laryngeal cancer with other stages. The indications of concurrent chemoradiotherapy were further discussed in this paper.
摘要: 喉癌是头颈部常见的恶性肿瘤之一，美国国立综合癌症网络（NCCN）临床实践指南认为同步放化疗是局部晚期喉癌最有效的器官保护策略，可在不降低患者生存率的前提下保留患者喉部。非T4（T1~3）、高淋巴结负担（N2~3）的喉癌患者可以从同步放化疗中受益，相较于其他分期的局部晚期喉癌更适合接受同步放化疗。本文就同步放化疗的适应证进行探讨。.
Keywords: chemotherapy; indications; laryngeal neoplasms; radiotherapy.
Copyright© by the Editorial Department of Journal of Clinical Otorhinolaryngology Head and Neck Surgery.